BGIM
SPRY icon

Brandywine Global Investment Management’s ARS Pharmaceuticals SPRY Stock Holding History

Brandywine Global Investment Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-106,400
Closed -$1.59M – 697
2024
Q3 		$1.59M Buy
+106,400
New +$1.27M 0.01% 559

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Brandywine Global Investment Management's SPRY Position: Q4 2024 in Review

Brandywine Global Investment Management sold out of ARS Pharmaceuticals (SPRY) in Q4 2024, closing a stake of 106,400 shares — an estimated $1.59M sold.

Brandywine Global Investment Management first reported a position in SPRY in Q3 2024 and held it in 1 quarter. The position peaked at $1.59M in Q3 2024. 165 funds tracked by Wall St. Rank hold SPRY as of Q4 2024.

  • Brandywine Global Investment Management reported no remaining ARS Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Brandywine Global Investment Management sold 106,400 ARS Pharmaceuticals shares in Q4 2024, an estimated $1.59M.
  • Brandywine Global Investment Management first reported a position in ARS Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Brandywine Global Investment Management's ARS Pharmaceuticals position peaked at $1.59M in Q3 2024.
  • 165 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2024.

Based on Brandywine Global Investment Management's 13F filing for Q4 2024, filed 12 Feb 2025.